Recombinant Proteins
- Name
- Recombinant Proteins
- Accession Number
- DBCAT000097
- Description
Proteins prepared by recombinant DNA technology.
- Drugs
Drug Drug Description Denileukin diftitox A recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. Rasburicase A recombinant form of urate-oxidase enzyme used to treat hyperuricemia following chemotherapy for leukemias and non-Hodgkin's lymphoma. Desmoteplase Investigated for use/treatment in cerebral ischemia and strokes. Maxy-G34 Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. Onercept Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease. Pegsunercept Investigated for use/treatment in rheumatoid arthritis. Albiglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Dulaglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Elosulfase alfa A lysosomal glycosaminoglycan (GAG)-specific enzyme indicated as an enzyme replacement therapy for Mucopolysaccharidosis type IV A. Corifollitropin alfa A FSH analogue indicated for Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Turoctocog alfa An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency). Dulanermin Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. Moroctocog alfa A recombinant Factor VIII used to treat hemophilia A to control bleeding. Antihemophilic factor (recombinant), PEGylated For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)... Elapegademase A recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency. Turoctocog alfa pegol Turoctocog alfa pegol is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to... Eftrenonacog alfa A recombinant Factor IX used to treat and prevent bleeding in hemophilia B. Endostar Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer. Luspatercept An erythroid maturation agent used to treat anemia secondary to beta thalassemia, myelodysplastic syndromes, and neoplasms. Albutrepenonacog alfa A recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B. Tagraxofusp A CD123-directed cytotoxin used to treat blastic plasmacytoid dendritic cell neoplasm. Pegilodecakin Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer). Talactoferrin alfa Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers. Rurioctocog alfa pegol A pegylated recombinant human coagulation factor VIII used to treat and prevent bleeding episodes in patients 12 years and above with hemophilia A. Alefacept A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. Cintredekin besudotox Investigated for use/treatment in brain cancer. Oportuzumab monatox Investigated for use/treatment in bladder cancer and head and neck cancer. Romiplostim A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). PRO-542 Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications. GI-5005 Investigated for use/treatment in hepatitis (viral, C). Rilonacept An IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder. Atacicept Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid). Baminercept Investigated for use/treatment in rheumatoid arthritis. Aflibercept A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy, and metastatic colorectal cancer Asfotase alfa An enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP). Trebananib Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon... Sotatercept Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others. Vanutide cridificar Vanutide cridificar has been investigated for the treatment of Alzheimer Disease. Abicipar Pegol Abicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration. Blisibimod Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis. Conbercept Conbercept has been investigated for the basic science of Age-related Macular Degeneration. Balugrastim Balugrastim has been used in trials studying the treatment of Solid Tumors. Albusomatropin Albusomatropin has been used in trials studying the treatment of Growth Hormone-Deficiency and Growth Hormone Deficiency. Dalantercept Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma). Ipafricept Ipafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors). Leridistim Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia). Asunercept Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme). Tebentafusp A bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat unresectable or metastatic uveal melanoma. DAS-181 DAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults). Valanafusp alfa Valanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I). ALT-801 ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia). Onasemnogene abeparvovec A gene therapy used to treat neonatal and infant patients with spinal muscular atrophy caused by bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. BNT162b1 SARS-CoV-2 Vaccine BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding... Tozinameran An mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus. Bizalimogene ralaplasmid Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade... Otlertuzumab Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia). Efineptakin alfa Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more... Pidacmeran Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults). BNT-162A1 BNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults). EpiVacCorona EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus . It is currently... Inbakicept Not Available Efanesoctocog alfa A recombinant DNA-derived, Factor VIII concentrate indicated for routine prophylaxis, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with hemophilia A. Tengonermin Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide.... Pegloticase A recombinant uricase used for the treatment of chronic gout in adult patients refractory to conventional therapy. Olipudase alfa A recombinant human acid sphingomyelinase used to treat Acid Sphingomyelinase Deficiency (ASMD) in children and adults. Valoctocogene roxaparvovec An adeno-associated virus serotype 5 (AAV5)-based gene therapy containing a coagulation factor VIII complementary DNA used to treat severe hemophilia A. MP-0250 Not Annotated Nadofaragene firadenovec A non-replicating adenoviral vector-based gene therapy used to treat high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). GI-6207 Not Annotated INO-4800 INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that... CVnCoV Vaccine The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate... Rocakinogene sifuplasmid Rocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma (GBM)). Eflepedocokin alfa Eflepedocokin alfa is a recombinant IL-22-Fc fusion protein manufactured in Chinese hamster ovary cells that is composed of 2 human interleukin 22 (IL-22) molecules linked to an immunoglobulin constant region... Famtozinameran A component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineages BA.4 and BA.5. Retlirafusp alfa Not Annotated CDX-1135 CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and... Tralesinidase alfa Tralesinidase alfa is a chimeric fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2. It is being investigated for the treatment of mucopolysaccharidosis type... Apadamtase alfa A recombinant human ADAMTS13 for enzyme replacement therapy in patients with congenital thrombotic thrombocytopenic purpura. Pegunigalsidase alfa A recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease. EDI-200 EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1. Telitacicept Not Annotated Acazicolcept Not Annotated Eftansomatropin alfa Eftansomatropin alfa (GX-H9) comprises a recombinant human growth hormone fused to hyFc, a synthetic hybrid Fc fragment. It is under investigation for the treatment of growth hormone deficiency. - Drugs & Drug Targets